1. Home
  2. BAP vs BIIB Comparison

BAP vs BIIB Comparison

Compare BAP & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Credicorp Ltd.

BAP

Credicorp Ltd.

HOLD

Current Price

$322.74

Market Cap

26.4B

Sector

Finance

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$186.64

Market Cap

27.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAP
BIIB
Founded
1889
1978
Country
Peru
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.4B
27.3B
IPO Year
1997
1996

Fundamental Metrics

Financial Performance
Metric
BAP
BIIB
Price
$322.74
$186.64
Analyst Decision
Buy
Buy
Analyst Count
5
25
Target Price
$309.60
$206.83
AVG Volume (30 Days)
363.7K
1.2M
Earning Date
05-14-2026
04-29-2026
Dividend Yield
3.46%
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.15
Revenue
N/A
$9,890,600,000.00
Revenue This Year
$23.26
N/A
Revenue Next Year
$8.62
N/A
P/E Ratio
$12.91
$88.14
Revenue Growth
N/A
2.22
52 Week Low
$193.13
$115.28
52 Week High
$380.20
$202.41

Technical Indicators

Market Signals
Indicator
BAP
BIIB
Relative Strength Index (RSI) 44.18 53.06
Support Level $316.99 $170.52
Resistance Level $363.15 $191.82
Average True Range (ATR) 14.17 5.45
MACD -1.74 1.04
Stochastic Oscillator 15.08 57.90

Price Performance

Historical Comparison
BAP
BIIB

About BAP Credicorp Ltd.

Credicorp Ltd is a Peruvian financial services company. It operates in four business lines, including Universal Banking, Insurance and Pensions, Microfinance, and Investment Management & Advisory. Its subsidiaries include Banco de Credito del Peru, Prima AFP, and Credicorp Capital. Geographically, the company operates in Peru, Colombia, Bolivia, Chile, Panama, the USA, and Mexico; the majority of its revenue is generated from Peru.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: